Dermatologic and nondermatologic uses of thalidomide

Annals of Pharmacotherapy

Volumn 37, Issue 9, 2003, Pages 1307-1320

  Nasca, Maria R ^a   Micali, Giuseppe ^a   Cheigh, Nina H ^b   West, Lee E ^c   West, Dennis P ^b,d  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Northwestern Medical Faculty Foundation   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Dermatologic disorders; Thalidomide

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; HYPNOTIC SEDATIVE AGENT; INTEGRIN RECEPTOR; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; AMENORRHEA; ANEMIA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANXIETY DISORDER; APPETITE DISORDER; ARTERY THROMBOSIS; BEHCET DISEASE; BLOOD TOXICITY; BRADYCARDIA; CARDIOTOXICITY; CELL TYPE; CHILL; CLINICAL TRIAL; COMA; CONFUSION; CONSTIPATION; CYTOKINE PRODUCTION; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; ENDOCRINE DISEASE; EOSINOPHILIA; ERECTILE DYSFUNCTION; ERYTHEMA; ERYTHEMA NODOSUM; EYE DISEASE; FACE EDEMA; FATIGUE; GAIT DISORDER; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEMATURIA; HEPATITIS; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; HYPOTHYROIDISM; IMMUNOMODULATION; IN VITRO STUDY; INSOMNIA; INSULIN RESISTANCE; KAPOSI SARCOMA; LARYNX EDEMA; LEUKOCYTE; LEUKOPENIA; LIBIDO DISORDER; LICHENOID ERUPTION; LIVER FAILURE; LUNG EDEMA; LUNG EMBOLISM; MENORRHAGIA; METEORISM; METRORRHAGIA; MOOD DISORDER; MUSCLE DISEASE; MYXEDEMA; NAUSEA; NECK PAIN; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHARYNGITIS; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURIGO; PRURITUS; PURPURA; RESPIRATORY TRACT DISEASE; REVIEW; RHINITIS; RIGIDITY; RISK BENEFIT ANALYSIS; SARCOIDOSIS; SCLERODERMA; SEIZURE; SIDE EFFECT; SINUSITIS; SKIN DISEASE; SKIN TOXICITY; SKIN ULCER; STEVENS JOHNSON SYNDROME; STUPOR; SWEATING; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; TERATOGENICITY; THEORY; THORAX PAIN; THROMBOCYTOPENIA; TINNITUS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; TREMOR; VEIN THROMBOSIS; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ANGIOGENESIS INHIBITORS; ANTI-HIV AGENTS; CLINICAL TRIALS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEPROSTATIC AGENTS; PATIENT SELECTION; PREGNANCY; THALIDOMIDE;

EID: 0041923722     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19255     Document Type: Review

References (187)

1. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-8.
2. Barnhill RL, Doll NJ, Millikan LE, Hastings RC. Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 1984;11:815-9.
3. Juffermans NP, Verbon A, Schultz MJ, Hack CE, van Deventer SJ, Speelman P, et al. Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens. Antimicrob Agents Chemother 2001;45:1547-9.
4. Ochonisky S, Revuz J. Thalidomide use in dermatology. Eur J Dermatol 1994;4:9-15.
5. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001;7:3349-55.
6. Vogelsang GB, Hess AD, Gordon G, Santos GW. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model. Transplantation 1986;41:644-7.
7. Turk JL, Hellmann K, Duke DI. Effect of thalidomide on the immunological response in local lymph nodes after a skin homograft. Lancet 1966;1:1134-6.
8. Murphy GP, Brede HD, Weber HW, Groenewald JH, Williams PD. Thalidomide immunosuppression in canine renal allotransplantation. J Med 1970;1:66-73.
9. Ostraat O, Riesbeck K, Qi Z, Eriksson T, Schatz H, Ekberg H. Thalidomide prolonged graft survival in a rat cardiac transplant model but had no inhibitory effect on lymphocyte function in vitro. Transplant Immunol 1996;4:117-25.
10. Uthoff K, Zehr KJ, Gaudin PB, Kumar P, Cho PW, Vogelsang G, et al. Thalidomide as replacement for steroids in immunosuppression after lung transplantation. Ann Thorac Surg 1995;59:277-82.
11. Charue D, Chauvin E, Revuz J, Bagot M. Thalidomide decreases the production of GM-CSF and TNT-α in the mixed epidermal cell-lymphocyte reaction. Eur J Dermatol 1996;6:373-6.
12. Keenan RJ, Eiras G, Burckart GJ, Stuart RS, Hardesty RL, Vogelsang G, et al. Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. Transplantation 1991;52:908-10.
13. Misery L, Peguet-Navarro J, Thivolet J, Faure M, Schmitt D, Claudy AL. Thalidomide does not affect in vitro mixed skin cell lymphocyte reactions. Clin Exp Dermatol 1994;20:85-6.
14. Santos-Mendoza T, Favila-Castillo L, Oltra A, Tamariz J, Labarrios F, Estrada-Parra S, et al. Thalidomide and its metabolites have no effect on human lymphocyte proliferation. Int Arch All Immunol 1996;111:13-7.
15. Gad SM, Shannon EJ, Krotoski WA, Hasting RC. Thalidomide induces imbalances in T-lymphocyte subpopulations in the circulating blood of healthy males. Lepr Rev 1985;56:35-9.
16. Nogueira AC, Neubert R, Helge H, Neubert D. Thalidomide and the immune system. 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci 1994;55:77-92.
17. Neubert R, Nogueira AC, Neubert D. Thalidomide and the immune system. 2. Changes in receptors on blood cells of a healthy volunteer. Life Sci 1992;51:2107-16.
18. McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachmann PJ, Lockwood CM. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th 1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995;99:160-7.
19. Verbon A, Juffermans NP, Speelman P, van Deventer SJ, ten Berge IJ, Guchelaar HJ, et al. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob Agents Chemother 2000;44:2286-90.
20. Haslett PA, Klausner JD, Makonkawkeyoon S, Moreira A, Metatratip P, Boyle B, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses 1999;15:1169-79.
21. Shannon EJ, Miranda RO, Morales MJ, Hasting RC. Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand J Immunol 1981;13:553-62.
22. Fernandez LP, Schlegel PG, Baker J, Chen Y, Chao NJ. Does thalidomide affect IL-2 response and production? Exp Hematol 1995;23:978-85.
23. Geist C, Wohrmann T, Schneider J, Zwingenberger K. Effects of thalidomide on the local Schwartzman reaction in mice and rabbits. FEMS Immunol Med Microbiol 1995;12:165-74.
24. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
25. Miyachi H, Azuma A, Hioki E, Iwasaki S, Kobayashi Y, Hashimoto Y. Cell type-/inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production and its enantio-dependence. Biochem Biophys Res Comm 1996;226:439-44.
26. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 2001;276:22382-7.
27. Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL, Schauf V, Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:5974-8.
28. Neubert R, Nogueira AC, Neubert D. Thalidomide derivatives and the immune system. 1. Changes in the pattern of integrin receptors and other surface markers on T lymphocyte subpopulations of marmoset blood. Arch Toxicol 1993;67:1-17.
29. Neubert R, Hinz N, Thiel R, Neubert D. Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide. Life Sci 1996;58:295-316.
30. Shannon EJ, Howe RC, McLean K, Hastings RC. Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules in vitro on the membranes of cells with immune potential. Immunopharmacol Immunotoxicol 1994;16:717-29.
31. Lovell CR, Hawk JLM, Calnan CD, Magnus IA. Thalidomide in actinic prurigo. Br J Dermatol 1983;108:467-71.
32. Bernal JE, Duran MM, Londoño F, Umaña A. Cellular immune effects of thalidomide in actinic prurigo. Int J Dermatol 1992;31:599-600.
33. Saylan T, Saltik I. Thalidomide in the treatment of Behçet's syndrome (letter). Arch Dermatol 1982;118:536.
34. Hamza M, Chaffai M, Ben Ayed H. [Treatment of Behçet's syndrome with thalidomide] French. (letter). Nouv Presse Med 1982;11:1080-1.
35. Bowers PW, Powell RJ. Effect of thalidomide on orogenital ulceration. BMJ 1983;287:799-800.
36. Rogé J, Testas P. [Thalidomide and Behçet's syndrome] French. (letter). Gastroenterol Clin Biol 1984;8:196.
37. Jenkins JS, Powell RJ, Allen BR, Littlewood SM, Maurice PDL, Smith NJ. Thalidomide in severe orogenital ulceration. Lancet 1984;22:1424-6.
38. Kürkçüoglu N, Atakan N, Eksioglu M. Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae (letter). Br J Dermatol 1985;112:632.
39. Grinspan D. Significant response of oral aphthosis to thalidomide treatment. J Am Acad Dermatol 1985;12:85-90.
40. de Wazieres B, Gil H, Magy N, Berthier S, Vuitton DA, Dupond JL. Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients. Rev Med Interne 1999;20:567-70.
41. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:443-50.
42. Menni S, Imondi D, Brancaleone W, Croci S. Recurrent giant aphthous ulcers in a child: protracted treatment with thalidomide. Pediatr Dermatol 1993;10:283-5.
43. Gardner-Medwin JMM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994;53:828-32.
44. Ramselaar CG, Boone RM, Kluin-Nelemans HC. Thalidomide in the treatment of neuro-Behçet's syndrome. Br J Dermatol 1986;115:367-70.
45. Trèves R, Arnaud M, Jacob P, Lubeau M, Tabaraud F, Burki F, et al. [Speculative amelioration of arthritis in Behçet disease with thalidomide. A case report] French. Rev Rhum Mal Osteoartic 1984;51:585.
46. Jorizzo JL, Schmalsteig FC, Solomon AR Jr, Cavallo T, Taylor RS 3d, Rudloff HB, et al. Thalidomide effects in Behçet's syndrome and pustular-vasculitis. Arch Intern Med 1986;5:365-71.
47. Munro CS, Cox NH. Pyoderma gangrenosum associated with Behçet's syndrome-response to thalidomide. Clin Exp Dermatol 1988;13:408-10.
48. Rustin MHA, Gilkes JJH, Robinson TWE. Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide. J Am Acad Dermatol 1990;23:941-4.
49. Larsson H. Case report treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217). J Intern Med 1990;228:405-7.
50. Postema PT, den Haan P, van Hagen PM, van Blankenstein M. Treatment of colitis in Behçet's disease with thalidomide. Eur J Gastroenterol Hepatol 1996;8:929-31.
51. Hamza MH. Behçet's disease, palmoplantar pustulosis and HLQA-B27: treatment with thalidomide (letter). Clin Exp Rheumatol 1990;8:427.
52. Paterson DL, Georghiou PR, Allworth AM, Kemp RJ. Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 1995;20:250-4.
53. Thompson C. Thalidomide effective for AIDS-related oral ulcers. Lancet 1995;346:1289.
54. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997;336:1487-93.
55. Ramirez-Amador VA, Esquivel-Pedraza L, Ponce-de-Leon S, Reyes-Teran G, Gonzalez-Guevara M, Ponce-de-Leon S, et al. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. Clin Infect Dis 1999;28:892-4.
56. Jacobson JM, Spritzler J, Fox L, Fahey JL, Jackson JB, Chernoff M, et al. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. J Infect Dis 1999;180:61-7.
57. Georghiou PR, Allworth AM. Thalidomide in painful AIDS-associated proctitis (letter). J Infect Dis 1992;166:939-40.
58. Solér RA, Migliorati C, van Waes H, Nadal D. Thalidomide treatment of mucosal ulcerations in HIV infection. Arch Dis Child 1996;74:64-5.
59. Strazzi S, Lebbe C, Geoffray C, Ablon G, Morel P, Verola O, et al. Aphthous ulcers in HIV-infected patients: treatment with thalidomide (letter). Genitourin Med 1992;68:424-5.
60. Verberkmoes A, Boer K, Wertheim PM, Bronkhorst CM, Lange GM. Thalidomide for genital ulcer in HIV-positive woman (letter). Lancet 1996;347:974.
61. Jacobson JM, Greenspan JS, Spritzler J, Fox L, Fahey JL, Jackson JB, et al. Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. J Infect Dis 2001;183:343-6.
62. Naafs B, Faber WR. Thalidomide therapy. An open trial. Int J Dermatol 1985;24:131-4.
63. Moisson YF, Janier M, Civatte J. Thalidomide for recurrent erythema multiforme (letter). Br J Dermatol 1992;126:92-3.
64. Cherouati K, Claudy A, Souteyrand P, Cambazard F, Vaillant L, Moulin G, et al. [Treatment by thalidomide of chronic multiforme erythema: its recurrent and continuous variants. A retrospective study of 26 patients] French. Ann Dermatol Venereol 1996;123:375-7.
65. Sheskin J. The treatment of lepra reaction in lepromatous leprosy: fifteen years' experience with thalidomide. Int J Dermatol 1980;19:318-22.
66. Product insert. Thalomid Capsules (thalidomide). Warren, NJ: Celgene Corporation, August 1998.
67. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-8.
68. Cole CH, Rogers PCJ, Pritchard S, Phillips G, Chan KW. Thalidomide in the management of chronic graft-versus-host disease in children following bone marrow transplantation. Bone Marrow Transplant 1994;14:937-42.
69. Parker PM, Chao N, Nademanee A, O'Donnell MR, Schmidt GM, Snyder DS, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995;86:3604-9.
70. Rovelli A, Anigo C, Nesi F, Balduzzi A, Nicolini B, Locasciulli A, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant 1998;21:577-81.
71. Browne PV, Weisdorf DJ, DeFor T, Miller WJ, Davies SM, Filipovich A, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 2000;26:865-9.
72. Moulin G, Bonnet F, Barrut D, Franc MP. [Treatment of Jessner - Kanof disease with thalidomide] French. Ann Dermatol Venereol 1983;110:611-4.
73. Guillaume JC, Moulin G, Dieng MT, Poli F, Morel P, Souteyrand P, et al. Crossover study of thalidomide vs. placebo in Jessner's lymphocytic infiltration of the skin. Arch Dermatol 1995;131:1032-5.
74. Benchikhi H, Joly P, Souteyrand P, Wechsler J, Revuz J, Bagot M. Traitement des infiltrats lymphocytaires cutanes benins par thalidomide (abstract). Ann Dermatol Venereol 1996;123(suppl 1):134A.
75. Carlesimo M, Giustini S, Rossi S, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 1995;32:866-9.
76. Solèr RA, Howard M, Brink NS, Gibb D, Tedder RS, Nadal D. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 1996;23:501-3.
77. Fife K, Howard MR, Gracie F, Phillips RH, Bower M. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998;9:751-5.
78. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:2593-602.
79. Grosshans E, Illy G. Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 1984;23:598-602.
80. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983;108:461-6.
81. Stevens RJ, Andujar C, Edwards CJ, Ames PR, Barwick AR, Khamashta MA, et al. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 1997;36:353-9.
82. Duong DJ, Spigel GT, Moxley RT 3rd, Gaspari AA. American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 1999;135:1079-87.
83. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 2000;39:218-22.
84. Ordi-Ros J, Cortes F, Cucurull E, Mauri M, Bujan S, Vilardell M. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 2000;27:1429-33.
85. Walchner M, Meurer M, Plewig G, Messer G. Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 2000;39:383-8.
86. Naafs B, Bakkers EJM, Flinterman J, Faber WR. Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermatol 1982;107:83-6.
87. Versapuech J, Beylot-Barry M, Doutre MS, Beylot C. [Subacute cutaneous lupus. Evolutive and therapeutic features of a series of 24 cases] French. Presse Med 2000;29:1596-9.
88. Knop J, Happle R, Vakilzadeh F, Macher E. Treatment of lupus erythematosus profundus with thalidomide (abstract). Arch Dermatol Res 1981;270:229.
89. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993;11:487-93.
90. Bessis D, Guillot B, Monpoint S, Dandurand M, Guilhou JJ. Thalidomide for systemic lupus erythematosus (letter). Lancet 1992;339:549-50.
91. Monastirli A, Georgiou S, Bolsen K, Pasmatzi E, Papapanagiotou A, Goerz G, et al. Treatment of porphyria cutanea tarda with oral thalidomide. Skin Pharmacol Appl Skin Physiol 1999;12:305-11.
92. Barnhill RL, McDougall AC. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. J Am Acad Dermatol 1982;7:317-23.
93. van den Broek H. Treatment of prurigo nodularis with thalidomide. Arch Dermatol 1980;116:571-2.
94. Winkelmann RK, Connolly SM, Doyle JA, Padilha-Goncalves A. Thalidomide treatment of prurigo nodularis. Acta Derm Venereol 1984;64:412-7.
95. Ferrandiz C, Carrascosa JM, Just M, Bielsa I, Ribera M. Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. Dermatology 1997;195:359-61.
96. Berger TG, Hoffman C, Thieberg MD. Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J Am Acad Dermatol 1995;33:837-8.
97. Herranz P, Pizarro A, De Lucas R, Arribas JR, Garcia-Tobaruela A, Pena JM, et al. Treatment of AIDS-associated prurigo nodularis with thalidomide. Clin Exp Dermatol 1998;23:233-5.
98. Rousseau L, Beylot-Barry M, Doutre MS, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol 1998;134:1045-6.
99. Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol 1998;39:835-8.
100. Estines O, Revuz J, Wolkenstein P, Bressieux JM, Roujeau JC, Cosnes A. [Sarcoidosis: thalidomide treatment in ten patients] French. Ann Dermatol Venereol 2001;128:611-3.
101. Oliver SJ, Kikuchi T, Kruger JG, Kaplan G. Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement. Clin Immunol 2002;102:225-36.
102. Oliver SJ, Moreira A, Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol 2000;97:109-20.
103. Silva SRB, Viana PCF, Lugon NV, Hoette M, Ruzany F, Lugon JR. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994;678:270-3.
104. Daly BM, Shuster S. Antipruritic action of thalidomide. Acta Derm Venereol 2000;80:24-5.
105. Lauret Ph. La thalidomide, vieux médicament, nouveaux espoirs. Nouv Dermatol 1982;1:7-9.
106. Carducci M, Mussi A, Afa G, Menaguale G, Sacerdoti G, Fazio M. Sindrome da anticorpi anti-fosfolipidi: terapia di un caso con talidomide ed antiaggreganti (abstract). In: Proceedings of: "VI Riunione - Giornate di Terapia in Dermovenereologia." Giardini-Naxos (ME), Italy, January 30-31, 1993.
107. Sosa M, Flores G, Estrada S, Orea M, Gomez Vera J. Comparative treatment between thalidomide and transfer factor in severe atopic dermatitis. Rev Alerg Mex 2001;48:56-64.
108. Lewis HB, Albert-Recht F, Walker W. Cold haemoagglutination disease treated by thalidomide. Br J Haematol 1968;15:322.
109. Pellacani G, Simonetti V, Conti A, Giusti G. Terapia con talidomide in un caso di eritema anulare centrifugo (abstract). In: Proceedings of the "72° Congresso SIDEV," Firenze, Italy, October 15-18, 1997.
110. Calandra P, Simonetti S, Biasini I. Erythema elevatum ac diutinum? Ann It Dermatol Clin Sper 1992;46:187-91.
111. Schnitzler L. [Beneficial effect of thalidomide in a case of Hailey - Hailey pemphigus. 1 years' trial] French. (letter). Ann Dermatol Venereol 1984;111:285-6.
112. Hadj-Rabia S, Bouscarat F, Piette F, Descamps V, Quesnel B, Bauters F, et al. Atteinte muqueuse au cours d'une kératose lichénoïde striée: efficacité du thalidomide (abstract). Ann Dermatol Venereol 1997;124 (suppl 1):258-9A.
113. Viraben R, Dupre A, Gorguet B. Pure cutaneous histiocytosis resembling sinus histiocytosis. Clin Exp Dermatol 1988;13:197-9.
114. Thomas L, Ducros B, Secchi T, Balme B, Moulin G. Successful treatment of adults' Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review. Arch Dermatol 1993;129:1261-4.
115. Meunier L, Marck Y, Ribeyre C, Meynadier J. Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment (letter). Br J Dermatol 1995;132:168.
116. Lair G, Marie I, Cailleux N, Blot E, Boullie MC, Courville P, et al. [Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide] French. Rev Med Interne 1998;19:196-8.
117. Camisa C, Popovsky JL. Effective treatment of oral erosive lichen planus with thalidomide. Arch Dermatol 2000;136:1442-3.
118. George SJ, Hsu S. Lichen planopilaris treated with thalidomide. J Am Acad Dermatol 2001;45:965-6.
119. Safa G, Joly P, Boullie MC, Thomine E, Lauret Ph. Treatment of Melkersson - Rosenthal syndrome with thalidomide. Ann Dermatol Venereol 1995;122:609-11.
120. Medeiros M Jr, Araujo MI, Guimaraes NS, Freitas LA, Silva TM, Carvalho EM. Therapeutic response to thalidomide in Melkersson - Rosenthal syndrome: a case report. Ann Allergy Asthma Immunol 2002;88:421-4.
121. Laugier P, Gilardi S. [Chronic erythematous oedema of the upper face (Degos). Morbihan disease (author's transl)] French. Ann Dermatol Venereol 1981;108:507-13.
122. Benchikhi H, Bodemer C, Fraitag S, Wechsler J, Delfau-Larue MH, Gounod N, et al. Treatment of cutaneous lymphoid hyperplasia with thalidomide: report of two cases. J Am Acad Dermatol 1999;40:1005-7.
123. Stamm C, Labeille B, Cotton JB, Greaume R, Misery L, David L, et al. Pyoderma gangrenosum infantile generalise (abstract). Ann Dermatol Venereol 1996;123:585.
124. Hecker MS, Lebwohl MG. Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol 1998;38:490-1.
125. Farrell AM, Black MM, Bracka A, Bunker CB. Pyoderma gangrenosum of the penis. Br J Dermatol 1998;138:337-40.
126. Federman GL, Federman DG. Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc 2000;75:842-4.
127. Eravelly J, Waters MF. Thalidomide in Weber - Christian disease (letter). Lancet 1977;1:251.
128. Moreira AL, Corral LG, Ye W, Johnson B, Stirling D, Muller GW, et al. Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retroviruses 1997;13:857-63.
129. Neubert R, Helge H, Neubert D. Thalidomide and the immune system. 4. Down regulation of the CD26 receptor, probably involved in the binding of the HIV components to T cells in primates. Life Sci 1995;56:407-20.
130. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 1996;10:1501-7.
131. Kaplan G, Thomas S, Fierer DS, Mulligan K, Haslett PA, Fessel WJ, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000;16:1345-55.
132. Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-α inhibitor: implications for clinical use. Clin Immunol Immunopathol 1996;81:219-23.
133. Gori A, Franzetti F, Marchetti G, Rossi C, Fusi ML, Ruzzante S, et al. Clinical and immunological improvement in a patient who received thalidomide treatment for refractory Mycobacterium avium complex infection. Clin Infect Dis 1998;26:184-5.
134. Sharpstone D, Rowbottom A, Francis N, Tovey G, Ellis D, Barrett M, et al. Thalidomide: a novel therapy for microsporidiosis. Gastroenterology 1997;112:1823-9.
135. Vicente T, Ortega A, Muñoz P, Diaz MD, Bouza E. In vitro activity of thalidomide against Mycobacterium avium complex (letter). Arch Intern Med 1993;153:534.
136. Ridoux O, Drancourt M. Lack of in vitro antimicrosporidian activity of thalidomide. Antimicrob Agents Chemother 1999;43:2305-6.
137. Breban M, Gombert B, Amor B, Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 1999;42:580-1.
138. McCormick PA, Scott F, Epstein O, Burroughs A, Scheuer PJ, McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J Hepatol 1994;21:496-9.
139. Thomas DA, Kantarjian HM. Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000;12:564-73.
140. Rajkumar S. Current status of thalidomide in the treatment of cancer. Oncology 2001;15:867-74.
141. Singhal S, Mehta J. Thalidomide in cancer. Biomed Pharmacother 2002;56:4-12.
142. McCarty MF. Thalidomide may impede cell migration in primates by down regulating integrin-beta chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 1997;49:123-31.
143. Davey PP, Ashrafian H. New therapies for heart failure: is thalidomide the answer? Q J Med 2000;93:305-11.
144. Bariol C, Meagher AP, Vickers CR, Byrnes DJ, Edwards PD, Hing M, et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol 2002;17:135-9.
145. Kaven C, Spraul CW, Zavazava N, Lang GK, Lang GE. Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro. Ophthalmologica 2001;215:284-9.
146. Schoeman JF, Ravenscroft A, Hartzenberg HB. Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess. Childs Nerv Syst 2001;17:370-2.
147. Sastry PS. Inhibition of TNF-alpha synthesis with thalidomide for prevention of acute exacerbations and altering the natural history of multiple sclerosis. Med Hypotheses 1999;53:76-7.
148. Parentin F, Da Pozzo S, Lepore L, Perissutti P. Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child. Ophthalmologica 2001;215:70-3.
149. Ip M, Gorin MB. Recurrence of choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide. Am J Ophthalmol 1996;122:594-5.
150. Scoville CD. Pilot study using the combination of methotrexate and thalidomide in the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2001;19:360-1.
151. Lehman TJ, Striegel KH, Onel KB. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr 2002;140:125-7.
152. Arrieta O, Ortiz-Reyes A, Rembao D, Calvillo M, Rivera E, Sotelo J. Protective effect of pentoxyfilline plus thalidomide against septic shock in mice. Int J Exp Pathol 1999;80:11-6.
153. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000;60:273-92.
154. Klausner JD, Makonkawkeyoon S, Akarasewi P, Nakata K, Kasinrerk W, Corral L, et al. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11:247-57.
155. Kaplan G. Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology 1994;191:564-8.
156. Arora M, Wagner JE, Davies SM, Blazar BR, Defor T, Enright H, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant 2001;7:265-73.
157. Wolkenstein P, Latarget J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
158. Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-14.
159. Powell RJ, Allen BR, Jenkins S, Steele L, Hunneyball I, Maurice PD, et al. Investigation and treatment of orogenital ulceration: studies on a possible mode of action of thalidomide. Br J Dermatol 1985;113(suppl 28):141-4.
160. Nasca MR, O'Toole EA, Palicharla P, West DP, Woodley DT. Thalidomide increases human keratinocyte migration and proliferation. J Invest Dermatol 1999;113:720-4.
161. Chao NJ, Parker PM, Niland JC, Wong RM, Dagis A, Long GD, et al. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease. Biol Blood Marrow Transplant 1996;2:86-92.
162. Boughton BJ, Sheehan TM, Wood J, O'Brien D, Butler M, Simpson A, et al. High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease. Ann Clin Biochem 1995;32:79-83.
163. Aronson IK, Yu R, West DP, van der Broek H, Antel J. Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures. Arch Dermatol 1984;120:1466-70.
164. Hunziker T, Krebs A. [Thalidomide in dermatology] German. Hautarzt 1983;34:66-72.
165. Ingen-Housz S, Venutolo E, Pinquier L, Cavelier-Balloy B, Dubertret L. Flageul B. [Erythema annulare centrifugum and relapsing polychondritis] French. Ann Dermatol Venereol 2000;127:735-9.
166. Clark TE, Edom N, Larson J, Lindsey LJ. Thalomid (thalidomide) capsules. A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Safety 2001;24:87-117.
167. Frances C, Elkhoury S, Gompel A, Becherel PA, Chosidow O, Piette JC. Transient secondary amenorrhea in women treated by thalidomide. Eur J Dermatol 2002;12:63-5.
168. Iqbal N, Zayed M, Boden G. Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes. Diabetes Care 2000;23:1172-6.
169. Nougué J, Nougué M, Bazex J, Hayek JP, Bidouze H. [Occurrence of a genital hemorrhage in prurigo nodularis treated with thalidomide] French. Ann Dermatol Venereol 1983:110:551-2.
170. Fowler R. Imria K. Thalidomide-associated hepatitis: a case report. Am J Hematol 2001;66:300-2.
171. Bastuji-Garin S, Ochonisky S, Bouche P, Gheradi RK, Duguet C, Djerradine Z, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002;119:1020-6.
172. Bez C, Lodi G, Sardella A, Della Volpe A, Carrassi A. Oral lichenoid lesions after thalidomide treatment (letter). Dermatology 1999;199:195.
173. Darvay A, Basarab T, Russell-Jones R, Thalidomide-induced toxic pustuloderma. Clin Exp Dermatol 1997;22:297-9.
174. Jacobsson C, Granström G. Clinical appearance of spontaneous and induced first and second branchial arch syndromes. Scand J Plast Reconstr Surg Hand Surg 1997;31:125-36.
175. Gardner-Medwin JM, Powell RJ. Thalidomide - the way forward. Postgrad Med J 1994;70:860-2.
176. Smithells RW, Newman CGH. Recognition of thalidomide defects. J Med Genet 1992;29:716-23.
177. Smithells RW. Thalidomide, absent appendix and sweating (letter). Lancet 1978;1:1042.
178. Rodier PM, Ingram JL, Tisdale B, Croog VJ. Linking etiologies in humans and animal models: studies of autism. Reprod Toxicol 1997;11:417-22.
179. Allen BR. Thalidomide. Br J Dermatol 2001;144:225-8.
180. Finnell RH, Waes JG, Eudy JD, Rosenquist TH. Molecular basis of environmentally induced birth defects. Ann Rev Pharmacol Toxicol 2002;42:181-208.
181. Onat D, Stahl W, Sies H. Stimulation of gap junctional intercellular communication by thalidomide and thalidomide analogs in human fetal skin fibroblasts (HFFF2) and in rat liver epithelial cells (WB-F344). Biochem Pharmacol 2001;62:1081-6.
182. Marriott JB, Muller G, Stirling D, Dalgleish AG. Immunotherapeutic and antitumor potential of thalidomide analogues. Expert Opin Biol Ther 2001;1:675-82.
183. Sadoh DR, Hawk JL, Panayiotopoulos CP. F-chronodispersion in patients on thalidomide. Clin Neurophysiol 1999;110:735-9.
184. Powell RJ, Gardner-Medwin JMM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994;70:901-4.
185. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999;21:319-30.
186. Corral LG, Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999;58(suppl 1):1107-13.
187. Di Carlo A, Passi S, Ippolito F. Primi risultati dell'impiego terapeutico della talidomide in uso topico (abstract). In: Proceedings of the "IX Riunione Giornate di Terapia in Dermovenereologia - Riunione Interregionale Centro Sud e Isole," Catania, Italy, October 23-25, 1998.